Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies

Currently, immune checkpoint inhibitors (ICIs) are widely considered the standard initial treatment for advanced non-small cell lung cancer (NSCLC) when there are no targetable driver oncogenic alternations. NSCLC tumors that have two alterations in tumor suppressor genes, such as liver kinase B1 (L...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Ichidai, Koyama, Junji, Itoigawa, Hideyuki, Hayai, Shunsaku, Morise, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477992/
https://www.ncbi.nlm.nih.gov/pubmed/37675220
http://dx.doi.org/10.3389/fonc.2023.1249237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477992/
https://www.ncbi.nlm.nih.gov/pubmed/37675220
http://dx.doi.org/10.3389/fonc.2023.1249237

Ejemplares similares